Study identification

EU PAS number

EUPAS32751

Study ID

32752

Official title and acronym

A Registry-Based Observational Study to Assess Maternal, Pregnancy, and Infant Outcomes Following Exposure to Ixekizumab (I1F-MC-B010)

DARWIN EU® study

No

Study countries

United States

Study status

Planned
Research institutions and networks

Institutions

Contact details

Elsie Grace

Primary lead investigator
Study timelines

Date when funding contract was signed

Actual:

Study start date

Planned:

Date of final study report

Planned:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Eli Lilly & Co.
Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

Non-EU RMP only